Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013.
An estimated 3.2 million persons in the United States have chronic infection with hepatitis C virus (HCV). Most new HCV transmissions occur among persons who inject drugs, often within the first few years of their injection drug use. During 2003-2012, reports of HCV infection increased from 15 to 54 cases per 100,000 among persons aged <30 years in Wisconsin, and 58% of persons in this age group with acute HCV infection reported injecting drugs (Wisconsin Division of Public Health, unpublished data, 2013). To increase detection of HCV infection, the Wisconsin Division of Public Health (WDPH) piloted a program during October 2012-October 2013 that offered rapid HCV testing to clients of four agencies providing outreach testing for HCV and human immunodeficiency virus infection, syringe exchange, counseling, and other harm reduction services to persons with drug dependence. During that period, 1,255 persons were tested using a rapid HCV test, and 246 (20%) of the results were positive. Most (72%) of the infections had not been reported to WDPH. A blood specimen for further testing was collected from 192 (78%) participants with positive HCV test results; among these participants, 183 were tested for HCV RNA using reverse transcription-polymerase chain reaction (RT-PCR), and these results were positive for 128 (70%) participants, indicating active infection. Use of the rapid HCV test detected previously unreported HCV infections and raised awareness of HCV. Persons identified with active HCV infection should be referred to medical care and counseled on ways to prevent HCV transmission to others.
Lauren J
LJ
Stockman
Sheila M
SM
Guilfoye
Andrea L
AL
Benoit
James M
JM
Vergeront
Jeffrey P
JP
Davis
D000293:Adolescent; D000328:Adult; D000368:Aged; D000914:Antibodies, Viral / Q000097:blood; D005260:Female; D016174:Hepacivirus / Q000276:immunology / Q000302:isolation & purification*; D006526:Hepatitis C / Q000097:blood / Q000175:diagnosis*; D006801:Humans; D007124:Immunoenzyme Techniques; D008297:Male; D008403:Mass Screening / Q000379:methods*; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D060888:Real-Time Polymerase Chain Reaction; D015203:Reproducibility of Results; D018570:Risk Assessment; D013997:Time Factors; D014922:Wisconsin; D055815:Young Adult
D000914:Antibodies, Viral; D012367:RNA, Viral